About Imvax
Imvax is a company based in Philadelphia (United States) founded in 2015 by David Andrews. Imvax has raised $203.83 million across 5 funding rounds from investors including Magnetar Capital, Invus and TLP Investments. The company has 50 employees as of December 31, 2021. Imvax offers products and services including IGV-001, Goldspire Platform, IHC-001, and IUC-001. Imvax operates in a competitive market with competitors including GT Medical Technologies, Basilea, BriaCell Therapeutics, Laminar Pharma and SOM Biotech, among others.
- Headquarter Philadelphia, United States
- Employees 50 as on 31 Dec, 2021
- Founders David Andrews
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Imvax, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$203.83 M (USD)
in 5 rounds
-
Latest Funding Round
$29 M (USD), Series C
Jan 29, 2025
-
Investors
Magnetar Capital
& 4 more
-
Employee Count
50
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Imvax
Imvax offers a comprehensive portfolio of products and services, including IGV-001, Goldspire Platform, IHC-001, and IUC-001.
Treats newly diagnosed glioblastoma through clinical trials
Captures tumor antigens for personalized cancer treatments
Preclinical treatment for solid tumors
Targets various solid tumor applications
People of Imvax
Unlock access to complete
Unlock access to complete
Funding Insights of Imvax
Imvax has successfully raised a total of $203.83M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $29 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Imvax
Imvax has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Magnetar Capital, Invus and TLP Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Magnetar Capital is engaged in alternative asset management.
|
Locked | Locked | Locked | |
|
Long-term private equity investments in transformational opportunities are pursued.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Imvax
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Imvax
Investment portfolio details for Imvax
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Imvax
Detailed financials for Imvax
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Imvax Comparisons
Peer comparison for Imvax
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Imvax
Imvax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GT Medical Technologies, Basilea, BriaCell Therapeutics, Laminar Pharma and SOM Biotech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Medical devices for brain tumor radiation therapy are provided.
|
|
| Locked | Locked | Locked |
Antibiotics, antifungals, and oncology drugs are developed for disease treatment.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of cancer
|
|
| Locked | Locked | Locked |
Melipathy-based drugs are developed for cancer, Alzheimer's, and inflammation treatments.
|
|
| Locked | Locked | Locked |
Developer of platform for screening compounds to treat rare diseases
|
Detailed competitors of Imvax
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Imvax
Complete news archive for Imvax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Imvax
Imvax was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Imvax is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Imvax is a funded company, having raised a total of $203.83M across 5 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Imvax is 50.
Imvax was founded in 2015 and is headquartered in Philadelphia, United States. Patient-specific vaccines and immunotherapies targeting malignant gliomas and other cancers are developed by the company within the biotechnology sector. The lead product, IGV-001, an autologous tumor cell vaccine designed to activate immune responses against cancer cells, is undergoing phase 1 clinical trials.
Imvax's top competitors include GT Medical Technologies, BriaCell Therapeutics and Basilea.
Imvax offers IGV-001, Goldspire Platform, IHC-001, and IUC-001.
Imvax has 5 investors. Key investors include Magnetar Capital, Invus, TLP Investments, HP Wild Holding, and Ziff Capital Partners.